inclusion criteria: * age ≥18 years. * informed consent for trial participation. * hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. * confirmation of sars-cov2 infection by nucleic acid test (nat) or equivalent non- nat test \[list of approved tests is in the pim\] collected within the prior 14 days. * onset of symptoms attributable to sars-cov2 infection occurred within 14 days before randomization. * hospitalized for the management of covid-19, with signs and/or symptoms suggestive of lower respiratory tract infection.

inclusion criteria: * age ≥18 years. * informed consent for trial participation. * hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. * confirmation of sars-cov2 infection by nucleic acid test (nat) or equivalent non- nat test \[list of approved tests is in the pim\] collected within the prior 14 days. * onset of symptoms attributable to sars-cov2 infection occurred within 14 days before randomization. * hospitalized for the management of covid-19, with signs and/or symptoms suggestive of lower respiratory tract infection.

inclusion criteria: age ≥18 years. informed consent for trial participation. hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. confirmation of sars-cov2 infection by nucleic acid test (nat) or equivalent non- nat test [list of approved tests is in the pim] collected within the prior 14 days. onset of symptoms attributable to sars-cov2 infection occurred within 14 days before randomization. hospitalized for the management of covid-19, with signs and/or symptoms suggestive of lower respiratory tract infection.

inclusion criteria: age ≥18 years. informed consent for trial participation. hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. confirmation of sars-cov2 infection by nucleic acid test (nat) or equivalent non- nat test [list of approved tests is in the pim] collected within the prior 14 days. onset of symptoms attributable to sars-cov2 infection occurred within 14 days before randomization. hospitalized for the management of covid-19, with signs and/or symptoms suggestive of lower respiratory tract infection.